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Reverse transcriptase polymerase chain reaction (RT-PCR) is
increasingly used to detect tumour cells in bone marrow, periph-
eral blood and peripheral stem cell harvests in a number of
different tumour types (Johnson et al, 1995). This method is more
sensitive than conventional tumour markers or antibody-based
techniques for the detection of small numbers of tumour cells,
though its clinical value remains controversial. Most studies report
a sensitivity of 1–10 cells detected in 1 ´ 107 mononuclear cells or
2 ml of whole blood in cell spiking experiments, but the frequency
of tumour cell detection in patient samples remains variable.
Although protocols vary in sample processing and RT-PCR
method, the consistent sensitivity in spiking experiments suggests
in most cases different RT-PCR protocols have been optimized to
similar sensitivities. A recent collaborative study by the European
Organization for Research and Treatment of Cancer demonstrated
the largest single contributing factor to this controversy is sample
processing (Keilholz et al, 1998). Some investigators isolate
mononuclear cells from whole blood by density gradient centrifu-
gation or concentrate the mononuclear cells by red cell lysis,
whereas others extract RNA directly from whole blood. We have
evaluated different approaches to sample processing in the context
of our studies of neuroblastoma cell detection in peripheral blood.
Neuroblastoma is a common solid tumour of childhood showing
a wide range of clinical behaviour, from localized tumours in
patients with a good prognosis to highly metastatic aggressive
tumours with an unfavourable outcome. Because the presence of
disseminating disease is associated with tumour relapse and poor
outcome (Rogers et al, 1989; Moss and Sanders, 1990; Moss et al,
1991), the need for early markers in the detection of metastasis
are important. Catecholamines are secreted by 98% of neuro-
blastomas, and therefore the first enzyme in the catecholamine
pathway, tyrosine hydroxylase (TH), has been used as a target for
RT-PCR detection of neuroblastoma cells in peripheral blood,
bone marrow and peripheral stem cell harvests (Burchill et al,
1994a, 1994b; Miyajima et al, 1995, 1996; Kuroda et al, 1997).
The clinical value of this technique in neuroblastoma is difficult to
assess, with reported frequency of neuroblastoma cell detection in
peripheral blood from stage 4 patients at diagnosis varying from
25% (Kuroda et al, 1997) to 100% (Miyajima et al, 1995).
This study was designed to compare the sensitivity and repro-
ducibility of RT-PCR for the detection of neuroblastoma cells in
whole blood using four common methods of blood sample
processing. The sensitivity of two of these methods was investi-
gated further in a small cohort of blood samples from untreated
patients with advanced stage 4 neuroblastoma.
MATERIALS AND METHODS
Cell lines and preparation of cell spikes
The neuroblastoma (IMR-32) cell line purchased from the
European Collection of Animal Cell Cultures (PHLS, UK) was
used in this study. These cells were grown in Dulbecco’s Modified
Eagle Medium (DMEM)-RPMI 1640 medium plus 10% fetal calf
serum (FCS). Experiments using whole blood into which known
numbers of IMR-32 cells were added were used to evaluate the
sensitivity, specificity and reproducibility of each process of
sample preparation. Four sets of cell spikes were prepared; to 2 ml
of whole blood, 0, 1, 10, 102, 103, 104 IMR-32 cells were added.
The one and ten cells were added by micromanipulation, greater
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suspension. Experiments using red cell lysis and isolation of
mononuclear fractions were performed four times, and experi-
ments with total or poly-A+ RNA isolated from whole blood were
performed five times.
Clinical samples
Blood (4 ml) was taken into EDTA (20 mM) containing tubes from
15 patients diagnosed with advanced stage 4 neuroblastoma
(International Neuroblastoma Staging System; Brodeur et al,
1988). All patients had catecholamine-secreting tumours that
expressed TH mRNA (results not shown). Blood samples were
divided into two 2-ml aliquots and total RNA extracted using
Ultraspec as described below. Blood samples from nine healthy
volunteers were included as negative controls. Total RNA from
patients or healthy volunteers was divided into two samples. One
of these samples was analysed by RT-PCR for TH mRNA in total
RNA, and, from the second, poly-A+ RNA was isolated and RT-
PCR for TH mRNA performed. Parental consent was given for all
children from whom blood was taken.
Preparation of cell spikes for RT-PCR analysis
Blood samples spiked with IMR-32 cells were processed in four
different ways.
(A) Red cell lysis
Red cells were lysed in whole blood cell spikes using a whole blood
erythrocyte lysing kit (R&D systems, Minneapolis), according to
manufacturer’s instructions. Briefly, to 2 ml of whole blood cell
spike, 2 ml of 1 ´ lysing buffer was added and vortexed. This was
incubated at room temperature for 10 min. Red cell lysis was visible
as darkening of the supernatant. The white cells were pelleted by
centrifugation for 5 min at 500 g. The supernatant was removed and
precipitated cells washed by resuspending in 2 ml of wash buffer,
vortexing and centrifugation for 5 min at 500 g. Cells were resus-
pended in 1 ml of phosphate-buffered saline (PBS) and added
directly to Ultraspec for isolation of total RNA as in (C) below.
(B) Isolation of white cell fraction
The white cell fraction was isolated from whole cell spikes using
Lymphoprep (Nycomed Pharma AS, Torshov, Norway). To 2 ml
of whole blood cell spikes, 4 ml of PBS was added. This was laid
over 3 ml of Lymphoprep and blood separated by centrifugation
for 20 min at 600 g. After centrifugation, the mononuclear cells
form a distinct band at the Lymphoprep/blood interface.
Mononuclear cells were isolated using a fine pastette and this frac-
tion washed twice in PBS (pelleting cells at 500 g ´ 5 min in
between). Isolated cells were resuspended in 1 ml of PBS and
added directly to Ultraspec for isolation of RNA as in (C) below.
(C) Total RNA extraction
Total RNA was extracted from whole blood using Ultraspec
(Biogenesis, Bournemouth, UK) as previously described (Burchill
et al, 1994a). Recovered RNA and its purity were measured by OD
at 260 and 280 nm. The quality of isolated RNA was confirmed by
separation of RNA (1 mg) in a 1 ´ TBE agarose gel and RT-PCR
analysis for b2 microglobulin using the primer pair, CTCGCGC-
TACTCTCTCTTTCT and TGTCGGATTGATGAAACCCAG, as
described below.
(D) Poly-A+ isolation
From total RNA isolated as in (C), poly-A+ RNA was isolated
using oligo(dT)25 beads (Dynal, Oslo, Norway). Briefly, to total
RNA [5 mg in 20 ml of diethyl pyrocarbonate-treated (depc)
water], 20 ml of the oligo(dT)25 beads in 2 ´ binding buffer were
added. Oligo(dT)25 beads were washed in 2 ´ binding buffer
(20 mM tris-HCl, pH 7.5; 1.0 M lithium chloride; 2.0 mM EDTA)
and resuspended at a concentration of 5.0 mg ml–1 in 2 ´ binding
buffer before use. Total RNA plus beads was incubated for 10 min
at room temperature. Beads with bound poly-A+ RNA were
isolated on a magnetic particle concentrator (MPC; Dynal), and
the supernatant removed and discarded. Isolated beads were
washed in 100 ml of 2 ´ binding buffer and resuspended in depc-
treated water (20 ml). Poly-A+ RNA was eluted from the beads by
heating at 65°C for 5 min. Samples were placed on the MPC and
supernatant containing poly-A+ retained.
Reverse transcriptase polymerase chain reaction
(RT-PCR)
Total or poly-A+ RNA was amplified for TH mRNA using 50
cycles of PCR as previously described (Burchill et al, 1994a). RT-
PCR was performed in a Microflow Omni PCR Workstation
(Astec Environmetal Systems, Weston-super-Mare, UK) and prod-
ucts amplified using a DNA Thermal Cycler 480 (Perkin Elmer,
NJ, USA). The primer pair used for amplification was ATC ACC
TGG TCA CCA AGT TC and GTG GTG TAG ACC TCC TTC
CA. For each sample, an RT-negative control (RT enzyme absent)
was included. Water negative controls with no total or poly-A+
RNA were also included. RNA extracted from IMR-32 cells was
used as a positive control in all experiments. Amplified products
were analysed by separation in a 1% agarose 1 ´ TBE gel with
fX174 RF DNA molecular weight markers (Gibco, Paisley, UK),
stained with ethidium bromide (0.5 mg ml–1) and products visual-
ized under UV light on a transilluminator.
The sensitivity of each method for the detection of TH mRNA
was calculated as a percentage:
number of samples positive
sensitivity =
or negative for TH mRNA
´ 100
number of samples spiked
or not spiked with tumour cells
Analysis of reverse transcriptase reaction
Total or poly-A+ RNA extracted from IMR-32 cells was heated in
depc water (10 ml) containing RNAase guard (0.5 ml) to 65°C for
5 min, spun at 13 000 g briefly and placed on ice. To this was
added 2 ml of reaction buffer (100 mM tris-HCl, 500 mM potassium
chloride, pH 8.3; Perkin Elmer Cetus), 2 mM of dGTP, dTTP and
dATP (Pharmacia Biotech, St Albans, UK), 16 mM magnesium
chloride (Sigma, Poole, UK), 0.5 ml of random hexamer primers
(Gibco), 10 U MMV reverse transcriptase (Pharmacia Biotech),
5 mCi of [a32P]dCTP (Amersham International, UK) and depc
water to make the final volume 20 ml. Samples were incubated at
37°C for 60 min, and then 80 ml of buffer A (10 mM tris-HCl, pH
7.5, 1 mM EDTA, 150 mM sodium chloride) added. To each
sample, 100 ml of phenol/chloroform/isoamyl alcohol (25:24:1;
Sigma) was added. The samples were vortexed and briefly spun at
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was collected, and unincorporated radionucleotide removed by
separation through a sepharose Nick column (Sepharose G50,
Pharmacia Biotech). Collected fractions (200 ml) were analysed by
electrophoresis (40 ml) in an acrylamide gel, which was dried and
exposed to film to produce an autoradiograph. Negative controls
containing no MMV reverse transcriptase or heat-inactivated RT
were included.
RESULTS
RT-PCR analysis for TH mRNA in blood samples spiked
with IMR-32 cells
RT-PCR for TH mRNA in blood samples spiked with IMR-32
cells generated a single band of 180 bp (Figure 1), as previously
described (Burchill et al, 1994a). No transcripts were identified in
RT-negative or water control samples (results not shown). The
Improved sample processing for RT-PCR 973
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Figure 1 Sensitivity of RT-PCR for the detection of known numbers of IMR-32 cells in whole blood spikes by RT-PCR for TH mRNA. (A) IMR-32 cells (0, 1, 10,
102, 103 or 104) were added to whole blood (2 ml). These spikes were set up four times and analysed for TH mRNA by RT-PCR after processing by: (A) red cell
lysis and total RNA extraction; (B) mononuclear cell fractionation and total RNA extraction; (C) whole blood and total RNA extraction; (D) whole blood and
poly-A+ RNA extraction. RT-PCR analysis for TH mRNA in total and poly-A+ RNA extracted from IMR-32 cells spiked into whole blood generated a single band of
180 bp, demonstrated on a 1% agarose gel stained with ethidium bromide and visualized under UV light. A single IMR-32 cell was detected in whole blood after
procedure B, C, or D. After red cell lysis (procedure A), the sensitivity of IMR-32 cell detection was reduced to 100 cells in 2 ml of whole blood. Primer dimers
were visible at the bottom of the gel. (B) Percentage of blood samples correct for detection of tumour cells by RT-PCR for TH mRNA. IMR-32 cells (0–104) were
spiked into 2 ml of whole blood and analysed for TH mRNA. The percentage of correct analysis is plotted against IMR-32 cell number added to whole bloodidentity of the 180-bp band was confirmed to be TH mRNA by
Southern blotting and direct sequence analysis. The sensitivity of
tumour cell detection by RT-PCR for each of the processing
methods was: (A), 60%; (B), 70%; (C), 92%; and (D), 100%; these
differences were statistically different using Fisher’s exact test
(P < 0.001). The specificity of TH mRNA detection by RT-PCR in
whole blood alone was 100% using any of the isolation procedures
(Figure 1B). Amplification for b2 microglobulin generated an
RT-PCR product of 136 bp in all isolated RNA or poly-A+ samples
(results not shown).
(A) Red cell lysis
In cell spiking experiments, it was possible to detect 100 IMR-32
cells diluted in 2 ml of whole human blood after red cell lysis and
extraction of total RNA (Figure 1). In four out of four separate
experiments, the level of detection was 100 cells. The sensitivity
of detecting TH mRNA in total RNA after red cell lysis was 60%
(Table 1).
(B) Isolation of white cell fraction
Using RT-PCR for TH mRNA in RNA extracted from mono-
nuclear cell fractions, it was possible to detect one cell in 2 ml of
whole blood (Figure 1). However, this level of sensitivity was only
achieved in one out of four experiments, a detection sensitivity of
ten cells in 2 ml of whole blood was found in two out of three
experiments. In three out of four experiments 100 cells were
detected, and in four out of four experiments 1000 cells. The sensi-
tivity of detecting TH mRNA after isolation of the white cell frac-
tion was 70% (Table 1).
(C) Total RNA extraction
TH mRNA was detected by RT-PCR in the one and ten cells
spiked into 2 ml of whole blood (Figure 1). TH mRNA was
detected in three out of five of the one cell and five out of five of
the ten cells in 2 ml of whole blood spikes. The sensitivity of
detecting TH mRNA in total RNA extracted from whole blood
was 92%.
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Table 1 Sensitivity and frequency of IMR-32 cell detection in whole blood spikes
Number of cells spiked into 2 ml of whole blood Sensitivity
0 1 10 102 103 104 (%)
(A) Red cell lysis (n =4 ) – – – + + + 6 0
(0) (0) (100) (100) (100)
(B) Mononuclear cell – + + + + + 70
fraction (n = 4) (25) (50) (75) (100) (100)
(C) Total RNA (n =5 ) – + + + + + 9 2
(75) (100) (100) (100) (100)
(D) Poly-A+ RNA (n = 5) – + + + + + 100
(100) (100) (100) (100) (100)
Whole blood (2 ml) was spiked with IMR-32 cells (1–104) and RNA (1 mg) analysed by RT-PCR for TH mRNA after: (A) red cell lysis and total RNA extraction;
(B) mononuclear cell fraction and total RNA extraction; (C) whole blood and total RNA extraction; (D) whole blood and poly-A+ RNA extraction. The sensitivity of
TH mRNA detection was scored; + = TH mRNA detected, – = TH mRNA not detected. The reliability of these results were assessed in four or five separate
experiments (n); the sensitivity of detection is given as a percentage in brackets.
TH
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+
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Total RNA         Poly-A
+ isolated from
1 mg        5 mg        10 mg        1 mg        5 mg        10 mg of total RNA
Number of samples positive for TH
mRNA out of 15 (% positive)
6            6             4              6            6             9
(40)        (40)        (27)          (40)        (40)        (60)
Figure 2 RT-PCR analysis of total RNA or poly-A+ RNA extracted from neuroblastoma patient blood samples. (A) Blood samples from 15 patients (1–15) with
advanced neuroblastoma were analysed for TH mRNA by RT-PCR of total or poly-A+ RNA. The frequency of TH mRNA detection in total and poly-A+ RNA
samples was compared. RNA (100 ng and 10 ng) extracted from IMR-32 cells was included as a positive control (+c), and samples containing no RNA as
negative controls (w). The figure shows amplification of 5 mg of total RNA and poly-A+ isolated from 10 mg of total RNA. m = jX174 RF DNA molecular weight
marker. (B) Summary of TH mRNA detection in total and poly-A+ RNA extracted from 15 blood samples from patients with advanced neuroblastoma(D) Poly-A+ isolation
After amplification of poly-A+ RNA for TH mRNA, it was possible
to detect one cell in 2 ml of whole blood (Figure 1). The detection
sensitivity after isolation of poly-A+ RNA from whole blood was
100%, TH mRNA was detected in five out of five experiments at
the level of one cell in 2 ml of whole blood (Table 1).
RT-PCR analysis of clinical samples
Analysing 1 mg of total RNA extracted from peripheral blood of
patients with stage 4 neuroblastoma, 6 out of 15 (40%) were posi-
tive for TH mRNA: patient samples 8, 10, 12, 13, 14 and 15
(Figure 2; Table 2). Identical results were obtained when 5 mg of
total RNA was analysed. However, when larger amounts of RNA
were analysed (10 mg), the frequency of TH mRNA detection was
reduced to 4 out of 15 (27%) (Figure 2B). Analysis of poly-A+
RNA isolated from matched blood samples gave the same results
when 1 and 5 mg of RNA were analysed, i.e. 6 out of 15 blood
samples were positive for TH mRNA (40%). The same samples
were positive after analysis of total and poly-A+ RNA. However,
when 10 mg of RNA were analysed, 9 out of 15 (60%) of samples
were positive for TH mRNA (Figure 2): the six blood samples
previously positive for TH mRNA after analysis of 1 and 5 mg of
RNA (patient samples 8, 10, 12, 13, 14, 15) and an additional three
(6, 9, 11). No TH mRNA was detected in total or poly-A+ RNA
extracted from the nine control normal blood samples (Figure 3).
All total RNA or poly-A+ RNA samples were positive for b2
microglobulin (results not shown).
Analysis of reverse transcriptase reaction
Radiolabelled cDNA was eluted from the Nick column in fractions
1, 2 and 3, after the column dead volume (400 ml) (Figure 4). The
peak of cDNA was recovered in fraction 2. Incubation of total or
poly-A+ RNA with heat-inactivated or no MMV reverse transcrip-
tase did not produce cDNA (Figure 4). The amount of cDNA
produced was proportional to the amount of total or poly-A+ RNA
added, but was lower in the poly-A+ than the total RNA samples.
DISCUSSION
Using RT-PCR for TH mRNA, it was possible to detect a single
IMR-32 neuroblastoma cell in 2 ml of whole blood, consistent with
previously published data (Burchill et al, 1994a,b). However, the
sensitivity and specificity of tumour cell detection was dependent
on the method of sample processing. No false positives were
detected in the cell spiking experiments, i.e. TH mRNA was not
detected in any of the unspiked blood samples. However, analysis
for TH mRNA after red cell lysis or mononuclear cell isolation led
to eight and six false negatives respectively. The high number of
false negatives suggests loss of tumour cells or isolation of poor
quality RNA using these two techniques. Loss of tumour cells from
the isolated mononuclear cell fraction using lymphoprep would
most likely explain the decreased reproducibility in procedure B.
Previous studies have demonstrated loss of melanoma cells after
density gradient separated mononuclear cell fractions (Keilholz,
1996). Degradation of mRNA can be a particularly difficult
problem when analysing circulating tumour cells in blood, bone
marrow or peripheral blood stem cells (PBSCs) because red blood
cells contain high levels of RNAases, which once released will
rapidly degrade mRNA (Jackson et al, 1991). Red cell lysis may
have lysed a proportion of tumour cells, which may then be
exposed to RNAases released from the red blood cells. Equally,
contamination of isolated RNA with a substance which reduces the
efficiency of the PCR amplification may also contribute to the false
negatives, e.g. prophyrin compounds derived from haem can inhibit
DNA polymerase activity (Higuchi, 1989).
The sensitivity of TH mRNA detection in whole blood spiked
samples by RT-PCR was 92% and 100%, after analysis of total RNA
or poly-A+ RNA respectively. This increase in sensitivity, when
compared with analysis of total RNA after red cell lysis (60%) or
mononuclear cell fractionation (70%), demonstrates analysis of
whole blood is more reliable, probably by avoiding loss of tumour
cells. The number of tumour cells lost after either red cell lysis or
mononuclear cell fractionation will vary depending on susceptibility
to lysis or size of different tumour cell populations. This hetero-
geneity of tumour cells within and between cancers strengthens the
case for analysis of whole blood. Although RNA isolated from
whole blood is often contaminated with DNA, providing primers for
the target to be amplified are selected in exons separated by an
intron, theoretically this should have no effect on the amplification
efficiency. However, large amounts of contaminating genomic DNA
are reported to reduce the efficiency of PCR amplification despite
the design of primers in different exons (M Willhauk, personal
communication). In this study, increasing the amount of total RNA
in an RT-PCR can result in loss of sensitivity. This inhibition of PCR
Improved sample processing for RT-PCR 975
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TH
23 7 5 4 16 8 9 +c w
Figure 3 RT-PCR analysis of poly-A+ RNA extracted from normal control
blood samples. Poly-A+ RNA was extracted from normal control blood (2 ml)
from nine age-matched children (1–9). RNA (100 ng and 10 ng) extracted
from IMR-32 cells was included as a positive control (+c), and samples
containing no RNA as negative controls (w)
Figure 4 cDNA synthesis from isolated total or poly-A+ RNA was assessed
by measuring incorporation of [a32P]dCTP. Total or poly-A+ mRNA (1, 5,
10 mg) was transcribed to cDNA as in the RT-PCR reaction, except dCTP
was replaced with radiolabelled [a32P]dCTP. Radiolabelled cDNA, separated
from unincorporated radioactivity using a Nick column, was found in fractions
1, 2 and 3 (after the 400-ml dead volume). Each fraction (1–5) is a volume of
200 ml. No cDNA was detected when total or poly-A+ RNA from 10 mg of RNA
was incubated in the absence of MMV reverse transcriptase (–RT)
23 5 4 12 3 5 4 12 3 5 4 12 3 5 4 1
23 5 4 12 3 5 4 12 3 5 4 12 3 5 4 1
Total
Poly-A+
–RT +RT +RT +RT
10 mg 5 mg 1 mgefficiency limits the amount of RNA and consequently blood
volume that may be analysed in any single PCR. Amplification of
poly-A+ RNA isolated from whole blood total RNA was more
sensitive than analysis of total RNA alone. Because poly-A+ RNA
comprises less than 5% of the total RNA within a cell, isolation of
poly-A+ RNA before reverse transcriptase would reduce the amount
of cDNA produced from tRNA and rRNA, and also reduce the level
of contaminating DNA. This allows analysis of larger amounts of
RNA and therefore blood volumes, leading to an increase in sensi-
tivity of tumour cell detection. Previous studies have suggested
analysis of whole blood RNA may be less sensitive than analysis of
RNA after red cell lysis (Gläser et al, 1997) or ficol separation
(Gläser et al, 1997; Jung et al, 1997). This study demonstrates isola-
tion of poly-A+from total RNA will increase the sensitivity of whole
blood analysis. The relationship between detection of TH mRNA in
patient samples after analysis of poly-A+ RNA rather than total
RNA was not linear; the frequency of TH mRNA detection in
patient samples was the same when 1 or 5 mg of total or poly-A+
RNA was analysed. The discrepancy between cell spiking experi-
ments, in which a linear relationship was found, and patient sample
analysis may reflect variations in the level of TH mRNA in cell line
and patient sample RNA. The heterogeneity of TH mRNA expres-
sion is currently under investigation in a wider cohort of cell lines
and primary tumours; neuroblastomas that do not express TH
mRNA would not be detected by this method. It is unlikely that
poly-A+ RNA isolated from patient samples would be contaminated
with DNA or a factor which is reducing the efficiency of the ampli-
fication any more than in the cell spikes.
The patient blood samples analysed in this study were taken at
diagnosis from patients with stage 4 disease, before treatment. This
group of patients was selected as they had clinically proven,
untreated stage 4 disease, and would therefore be most likely to have
circulating tumour cells. However, circulating tumour cells were
only detected in 60% of stage 4 patients using the most sensitive
method of sample processing, poly-A+ isolation. Failure to detect
circulating tumour cells in all stage 4 blood samples probably
reflects the random shedding of tumour cells into the circulation
(Fidler, 1990). Preliminary studies suggest the detection of circu-
lating tumour cells in stage 4 neuroblastoma patients at diagnosis
may identify a subgroup of patients with a worse prognosis than
those patients in which tumour cells are not detected (Burchill et al,
1994b; Miyajima et al, 1995; Kuroda et al, 1997), though the
number of patients in these studies are small. The clinical signifi-
cance of tumour cell detection by RT-PCR for TH mRNA is
currently being investigated nationally through the United Kingdom
Children’s Cancer Study Group (study number NB 9305).
Although RT-PCR detection of circulating tumour cells has been
shown to increase the sensitivity of small-volume disease detec-
tion, the clinical significance of detecting low levels of disease
remains unclear, and transfer of the technology into a clinical
setting has been slow. This reflects the lack of good quality, long-
term clinical outcome studies and the technical challenges associ-
ated with RNA-based assays. These studies demonstrate collection
of whole blood samples into EDTA, rapidly frozen at –80°C, and
subsequent extraction of poly-A+ RNA is a suitable and reliable
method for the processing of blood samples before analysis by RT-
PCR. Thus, sample collection in the clinic can be as uncomplicated
as taking a whole blood sample into EDTA and freezing at –80°C,
this will ease sample collection for the much needed multicentre
quality controlled studies to evaluate the clinical significance of
this technique in small-volume disease detection.
In summary, these studies support the hypothesis that sample
preparation, RNA extraction and cDNA synthesis account for
most of the heterogeneity of RT-PCR assay results in patient
samples. No false negatives or positives were detected after RT-
PCR analysis of poly-A+ RNA isolated from whole blood cell
spikes, and an increased frequency of tumour cell detection was
found in patient blood samples. Further studies are required to
investigate the relationship between tumour cell shedding,
frequency of blood sampling and the blood volume analysed,
which are important biological variables. Molecular staging of
human cancers by evaluating the primary tumour and the circula-
tion of potentially metastatic cells is a vital and attainable goal for
clinical cancer research. Existing procedures are an important
beginning for evaluation of the clinical significance of such
methods, but progress can only be made if we rigorously evaluate
them scientifically and technically.
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